Recruiting NA INTERVENTIONAL 1-arm NCT06046794

Efficacy of First-Line Gemcitabine Chemotherapy in GemCore+ Metastatic Pancreatic Adenocarcinoma Patients (GemSign-01)

Phase IV Study Assessing Efficacy of First-Line Chemotherapy With Gemcitabine in GemCore+ Metastatic Pancreatic Adenocarcinoma Patients Ineligible to FOLFIRINOX Treatment

Sponsor: Institut Paoli-Calmettes

Conditions Cancer Of Pancreas

Interventions Analyze of GemCore status

Updated 7 times since 2023 Last updated: Jun 10, 2025 Started: May 23, 2024 Primary completion: Nov 1, 2027 Completion: Nov 1, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This NA trial investigates Cancer Of Pancreas and is currently actively recruiting participants. Institut Paoli-Calmettes leads this study, which shows 7 recorded versions since 2024 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

7 versions recorded

Jul 2025 — Present [monthly]

Recruiting NA
Nov 2024 — Jul 2025 [monthly]

Recruiting NA

Status: Not Yet Recruiting → Recruiting
Sep 2024 — Nov 2024 [monthly]

Not Yet Recruiting NA
Jul 2024 — Sep 2024 [monthly]

Not Yet Recruiting NA
Jan 2024 — Jul 2024 [monthly]

Not Yet Recruiting NA

▶ Show 2 earlier versions

Dec 2023 — Jan 2024 [monthly]

Not Yet Recruiting NA
Oct 2023 — Dec 2023 [monthly]

Not Yet Recruiting NA

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Institut Paoli-Calmettes

Data source: Institut Paoli-Calmettes

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Marseille, France